Q2 2025 Hansa Biopharma AB Earnings Call Transcript
Key Points
- Hansa Biopharma AB (LTS:0RC7) achieved a 76% increase in IDEFIRIX sales revenue in Q2 2025 compared to Q2 2024.
- The company successfully raised SEK232 million to support key data readouts in the second half of 2025.
- Hansa Biopharma AB completed enrollment of the Phase III PAES study in kidney transplantation, with data readout expected in mid-2026.
- The company secured access for IDEFIRIX in two additional markets, Australia and Switzerland, bringing the total to 20 countries.
- Hansa Biopharma AB reported a 27% increase in total revenue for the first half of 2025 compared to the first half of 2024.
- The pause of the Euro transplant prioritization program in Germany negatively impacted Q2 revenues from the country.
- SG&A expenses in Q2 2025 included a SEK21 million reserve for restructuring, impacting overall expenses.
- R&D expenses in Q2 2025 were 4.4% higher compared to Q2 2024, partly due to restructuring charges.
- The company faces quarterly volatility in performance due to the unpredictability of the organ allocation market.
- The restructuring process led to the departure of experienced colleagues, reflecting the challenging macro environment.
Good day, and welcome to the Hansa Biopharma second-quarter earnings conference call. (Operator Instructions)
Please note today's event is being recorded. I would now like to turn the conference over to Renee Aguiar-Lucander, Chief Executive Officer. Please go ahead.
©- -
Thank you. Good afternoon, and good morning, everyone, and welcome to the Hansa Biopharma conference call to review Q2 and half-year results for 2025. I'm Renee Aguiar-Lucander, CEO of Hansa Biopharma. And joining me today is Evan Ballantyne, Chief Financial Officer; Hitto Kaufmann, Chief Scientific and Technology Officer; and Maria Törnsén, Chief Operating Officer and President of the US.
Please turn to slide 2. Please allow me to draw your attention to the fact that we will be making forward-looking statements during this presentation, and you should therefore apply appropriate caution.
Please turn to slide 3. So this -- today, we'll discuss the progress we've made
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
